MALVERN, Pa., July 15, 2026
MAXONA Pharmaceuticals has received U.S. FDA Investigational New Drug (IND) clearance to initiate a Phase 2 clinical trial evaluating MAX-001, its investigational non-opioid, non-NSAID oral therapy for the treatment of acute pain. The regulatory milestone represents a significant advancement in the company’s mission to develop safer alternatives to opioid-based pain management while addressing one of the most pressing unmet medical needs in modern healthcare. MAX-001 is a proprietary extended-release formulation of nefopam, a widely studied analgesic that has been used for decades in multiple international markets but remains a New Molecular Entity (NME) in the United States. The FDA’s clearance enables MAXONA to rapidly advance clinical development by launching the randomized, controlled MAX-001-201 Phase 2 trial, with patient enrollment expected to begin in the coming months. The announcement underscores growing industry efforts to expand innovative pain management options capable of delivering effective analgesia without the addiction risks commonly associated with opioid medications.
MAX-001 Targets Acute Pain with a Novel Non-Opioid Approach
MAX-001 has been designed as a proprietary optimized extended-release (ER) oral formulation of nefopam, delivering both a rapid onset of pain relief and sustained analgesic activity. Unlike opioid medications or nonsteroidal anti-inflammatory drugs (NSAIDs), MAX-001 works through a triple monoamine neurotransmitter reuptake inhibition mechanism, primarily affecting norepinephrine, followed by serotonin and dopamine pathways. If approved, MAX-001 could become the first triple monoamine reuptake inhibitor indicated for acute pain treatment in the United States. Nefopam has accumulated more than four decades of clinical experience across Europe and other international markets, where extensive clinical studies have demonstrated favorable safety and efficacy profiles in treating both acute and chronic pain. MAXONA aims to leverage this well-established clinical experience while generating new U.S. clinical data to support regulatory approval of its proprietary formulation for American patients seeking effective non-opioid pain management solutions.
Clinical Development Builds on Positive Phase 1 Results
The upcoming MAX-001-201 Phase 2 study follows encouraging results from the completed Phase 1 MAX-001-101 trial, which demonstrated that the investigational therapy exhibited dose-proportional pharmacokinetics, was safe and well tolerated, and produced no serious adverse events, severe treatment-related adverse events, or clinically significant abnormalities in laboratory testing, electrocardiograms, or vital signs. Company leadership emphasized that the FDA clearance represents a critical step toward expanding treatment options for patients suffering from acute and chronic pain. Shawn Fatholahi, President and Chief Executive Officer of MAXONA Pharmaceuticals, noted that the company remains committed to delivering additional safe, effective non-opioid therapies for U.S. patients while continuing close collaboration with the FDA throughout the development program. Medical experts supporting the program highlighted the substantial unmet need for innovative analgesics capable of providing rapid and sustained pain relief without the dependence risks associated with opioid medications.
Advertisement
According to Dr. Roy Freeman, Senior Medical Advisor to MAXONA Pharmaceuticals, extensive international clinical experience with nefopam provides a strong scientific foundation for the continued evaluation of MAX-001, while the Phase 2 program will generate randomized, controlled evidence supporting its clinical potential in postoperative acute pain management. As the healthcare industry continues prioritizing safer alternatives to opioid therapy amid ongoing concerns surrounding opioid misuse and addiction, MAXONA Pharmaceuticals is positioning MAX-001 as a promising next-generation pain treatment that combines established pharmacology with proprietary drug delivery technology. The FDA IND clearance marks an important regulatory milestone that advances the company toward later-stage clinical development and potentially expands the future landscape of non-opioid pain therapeutics.
Source: MAXONA Pharmaceuticals press release
